JP2021519783A5 - - Google Patents

Info

Publication number
JP2021519783A5
JP2021519783A5 JP2020552849A JP2020552849A JP2021519783A5 JP 2021519783 A5 JP2021519783 A5 JP 2021519783A5 JP 2020552849 A JP2020552849 A JP 2020552849A JP 2020552849 A JP2020552849 A JP 2020552849A JP 2021519783 A5 JP2021519783 A5 JP 2021519783A5
Authority
JP
Japan
Prior art keywords
alkyl
cancer
independently selected
heterocycloalkyl
members
Prior art date
Application number
JP2020552849A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019191470A5 (https=
JP2021519783A (ja
JP7350005B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/024645 external-priority patent/WO2019191470A1/en
Publication of JP2021519783A publication Critical patent/JP2021519783A/ja
Publication of JPWO2019191470A5 publication Critical patent/JPWO2019191470A5/ja
Publication of JP2021519783A5 publication Critical patent/JP2021519783A5/ja
Priority to JP2023090963A priority Critical patent/JP2023101762A/ja
Application granted granted Critical
Publication of JP7350005B2 publication Critical patent/JP7350005B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020552849A 2018-03-30 2019-03-28 Mat2aの複素二環式阻害剤、およびがんの治療のための使用方法 Active JP7350005B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023090963A JP2023101762A (ja) 2018-03-30 2023-06-01 Mat2aの複素二環式阻害剤、およびがんの治療のための使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018081328 2018-03-30
CNPCT/CN2018/081328 2018-03-30
PCT/US2019/024645 WO2019191470A1 (en) 2018-03-30 2019-03-28 Heterobicyclic inhibitors of mat2a and methods of use for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023090963A Division JP2023101762A (ja) 2018-03-30 2023-06-01 Mat2aの複素二環式阻害剤、およびがんの治療のための使用方法

Publications (4)

Publication Number Publication Date
JP2021519783A JP2021519783A (ja) 2021-08-12
JPWO2019191470A5 JPWO2019191470A5 (https=) 2022-04-05
JP2021519783A5 true JP2021519783A5 (https=) 2022-04-05
JP7350005B2 JP7350005B2 (ja) 2023-09-25

Family

ID=67439309

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020552849A Active JP7350005B2 (ja) 2018-03-30 2019-03-28 Mat2aの複素二環式阻害剤、およびがんの治療のための使用方法
JP2023090963A Withdrawn JP2023101762A (ja) 2018-03-30 2023-06-01 Mat2aの複素二環式阻害剤、およびがんの治療のための使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023090963A Withdrawn JP2023101762A (ja) 2018-03-30 2023-06-01 Mat2aの複素二環式阻害剤、およびがんの治療のための使用方法

Country Status (21)

Country Link
US (1) US11524960B2 (https=)
EP (1) EP3774805B1 (https=)
JP (2) JP7350005B2 (https=)
KR (1) KR102736073B1 (https=)
CN (1) CN111936499B (https=)
AR (1) AR115326A1 (https=)
AU (1) AU2019243289B2 (https=)
BR (1) BR112020020104A2 (https=)
CA (1) CA3094476C (https=)
EA (1) EA202092320A1 (https=)
ES (1) ES2973114T3 (https=)
HU (1) HUE066282T2 (https=)
IL (1) IL277665B2 (https=)
MA (1) MA52232A (https=)
MX (1) MX2020010005A (https=)
PH (1) PH12020551507A1 (https=)
PL (1) PL3774805T3 (https=)
SG (1) SG11202009195WA (https=)
TW (1) TWI719437B (https=)
UA (1) UA127059C2 (https=)
WO (1) WO2019191470A1 (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020123395A1 (en) 2018-12-10 2020-06-18 Ideaya Biosciences, Inc. 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
MX2021007833A (es) * 2018-12-27 2021-10-26 Les Laboratoires Servier Sas Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer.
MA54608B1 (fr) * 2018-12-27 2023-02-28 Servier Lab Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
AR119046A1 (es) * 2019-05-31 2021-11-17 Agios Pharmaceuticals Inc Inhibidores heterobicíclicos de mat2a y su uso para el tratamiento de diversos tipos de cáncer
WO2021252679A1 (en) * 2020-06-10 2021-12-16 Ideaya Biosciences, Inc. 2-aminoquinazolinone derivatives as methionine adenosyltransferase 2a inhibitors
US20240208965A1 (en) * 2020-06-10 2024-06-27 Ideaya Biosciences, Inc. Heteroaryl alkylene substituted 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
US20230227409A1 (en) * 2020-06-10 2023-07-20 Ideaya Biosciences, Inc. Quinolinone derivatives as methionine adenosyltransferase 2a inhibitors
WO2021252680A1 (en) * 2020-06-10 2021-12-16 Ideaya Biosciences, Inc. 4-arylquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
WO2022052924A1 (zh) * 2020-09-11 2022-03-17 上海凌达生物医药有限公司 一类含氮稠环类化合物的制备方法和用途
TW202214630A (zh) * 2020-09-12 2022-04-16 大陸商成都倍特藥業股份有限公司 甲硫胺酸腺苷轉移酶抑制劑、其製備方法及應用
CN115960099A (zh) * 2020-09-24 2023-04-14 上海凌达生物医药有限公司 一类芳环或芳基杂环并吡啶酮类化合物、药物组合物及其应用
CN114507231B (zh) * 2020-11-17 2025-06-03 南京再明医药有限公司 内酰胺类化合物及其制备方法
CN114634521A (zh) * 2020-12-15 2022-06-17 首药控股(北京)股份有限公司 Dna-pk选择性抑制剂及其制备方法和用途
WO2022143864A1 (zh) 2020-12-31 2022-07-07 江苏先声药业有限公司 三环类化合物及用途
CN115141202A (zh) * 2021-03-29 2022-10-04 武汉人福创新药物研发中心有限公司 嘧啶并吡嗪酮化合物及其用途
WO2022222911A1 (zh) * 2021-04-19 2022-10-27 武汉人福创新药物研发中心有限公司 嘧啶酮化合物及其用途
CN117412967A (zh) * 2021-06-02 2024-01-16 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a抑制剂
CN118434722A (zh) 2021-10-20 2024-08-02 英矽智能科技知识产权有限公司 甲硫氨酸腺苷转移酶2a(mat2a)抑制剂及其用途
CN118265700A (zh) * 2021-11-09 2024-06-28 上海海雁医药科技有限公司 取代的萘啶酮衍生物、其药物组合物及应用
CN114028572B (zh) * 2021-11-30 2022-11-25 清华大学 Mat2a抑制剂用于治疗哮喘的新应用
CN118414338A (zh) * 2021-12-21 2024-07-30 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a的杂环抑制剂
WO2023125737A1 (en) * 2021-12-29 2023-07-06 Silexon Ai Technology Co., Ltd. Heterocyclic compounds and use thereof
KR20240138099A (ko) * 2022-01-26 2024-09-20 쑤저우 젠하우스 바이오 컴퍼니 리미티드 Mtap 결실 암을 치료하기 위한 메티오닌 아데노실트랜스퍼라제 2a 억제제
WO2023169554A1 (zh) * 2022-03-11 2023-09-14 赛诺哈勃药业(成都)有限公司 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用
EP4545531A1 (en) 2022-06-27 2025-04-30 CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Tricyclic compounds and uses thereof
CN117430596A (zh) * 2022-07-13 2024-01-23 上海海和药物研究开发股份有限公司 二并环类mat2a抑制剂及其用途
JP2025533273A (ja) 2022-10-13 2025-10-03 ハンミ ファーマシューティカルズ カンパニー リミテッド 新規なトリサイクル誘導体化合物及びその用途
WO2024183778A1 (zh) * 2023-03-06 2024-09-12 甘李药业股份有限公司 一种甲硫氨酸腺苷转移酶2a抑制剂及其医药用途
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
CN121399128A (zh) * 2023-06-14 2026-01-23 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a杂环抑制剂的晶型、其制备方法及用途
WO2025000265A1 (en) * 2023-06-28 2025-01-02 Silexon Ai Technology Co., Ltd. Heterocyclic compounds usefull as sos1 inhibitor
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025088571A1 (en) * 2023-10-26 2025-05-01 Astrazeneca Ab Crystalline forms of tead inhibitor
CN117567473B (zh) * 2023-11-09 2025-07-04 中国药科大学 一种靶向同源二聚体的抑制剂及其制备方法与应用
WO2025166257A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Amide substituted triheterocyclic guanidino compounds as prmt5 inhibitors
WO2025166274A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Tricyclic guanidino compounds as prmt5 inhibitors
WO2025166229A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Tricyclic amidino compounds as prmt5 inhibitors
WO2025166215A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Triheterocyclic guanidino compounds as prmt5 inhibitors
WO2025166260A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Amide substituted tricyclic guanidino compounds as prmt5 inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002517486A (ja) 1998-06-12 2002-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド p38のインヒビター
US6576420B1 (en) 1998-06-23 2003-06-10 Regents Of The University Of California Method for early diagnosis of, and determination of prognosis in, cancer
WO2004014378A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
SG10201407012XA (en) * 2009-10-29 2014-11-27 Genosco Kinase inhibitors
US20160115164A1 (en) * 2014-10-22 2016-04-28 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) * 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AU2017291812B2 (en) * 2016-07-05 2023-12-14 Dana-Farber Cancer Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof
CR20190157A (es) * 2016-08-31 2019-08-13 Agios Pharmaceuticals Inc Inhibidores de procesos metabólicos celulares
WO2018039972A1 (en) * 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes

Similar Documents

Publication Publication Date Title
JP2021519783A5 (https=)
JPWO2019191470A5 (https=)
CN114430739A (zh) Egfr抑制剂、组合物及其制备方法
CA2807620C (en) Pharmaceutically active compounds as axl inhibitors
KR102166002B1 (ko) 섬유 아세포 성장 인자 수용체 키나아제 억제제인 인다졸계 화합물 및 이의 제조와 응용
CN113316574A (zh) Shp2抑制剂及其应用
CN114430741A (zh) Egfr抑制剂、组合物及其制备方法
RU2010128107A (ru) Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp
CN109069504A (zh) 氨基噻唑化合物及其用途
JP2021501145A5 (https=)
JP2005534669A5 (https=)
KR20150023870A (ko) 이미다조옥사진 화합물에 의한 항종양 효과 증강제
JP2020534300A5 (https=)
CN116113416A (zh) 四环类衍生物、其制备方法和其医药上的用途
JPWO2021055295A5 (https=)
CN116323590A (zh) 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
JPWO2021252661A5 (https=)
JP4852605B2 (ja) 放射線治療増強剤
JPWO2021195128A5 (https=)
CN110240587A (zh) 一类芳基二氟苄基醚类化合物、制备方法及用途
JPWO2021076688A5 (https=)
JP2005531563A5 (https=)
CA3195465A1 (en) Succinate and crystal form thereof as therapeutics
JPWO2019213570A5 (https=)
WO2024118596A1 (en) Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof